NICE approve Waldmann's MS drug for use in UK hospitals

NICE approve Waldmann's MS drug for use in UK hospitals

NICE approval of a multiple sclerosis drug therapy developed by Herman Waldmann and his group will see Lemtrada (alemtuzumab) rolled out in NHS hospitals from September. 

Approval by the UK's National Institute for Health and Care Excellence (NICE) acknowledges Lemtrada as a clinically effective and cost effective treatment for the disease and is a landmark in the development of the drug that has taken decades to get to market. The move follows approval by the European Medicines Agency in September 2013.

Lemtrada developed in collaboration with Cambridge University ''is a major step forward in the treatment of people with multiple sclerosis'' said Nick Eijke, director for policy and research at the MS Society.   

Further reading: 

 

Wednesday, May 28, 2014 - 15